INTRODUCTION
Since surfactants became commercially available in 1990 reports have documented a significant drop in infant mortality for the years 1990 to 1992. These reports examined the period immediately following the introduction of surfactant within selected hospital populations, within the US population, and within regional populations. 1 ± 5 Most of these reports, however, have not examined RDS-specific mortality, but have used infant or neonatal mortality as an indicator of the effect of surfactant. Whereas this strategy has the virtue of not missing mortality that might be related to a death associated with RDS, it does not address the direct effect that surfactant therapy may have had on mortality directly associated with the disease process it is intended to prevent. In addition, examining RDS-specific mortality provides the opportunity to examine changes in assignment of causes of death that may have evolved as physician expectations change as a result of the expected impact of surfactant on RDS. Studies in the presurfactant era have demonstrated a consistent decline in RDS-specific mortality. 6 However, more recent RDS-specific mortality studies have documented an accelerated decline. Most recently Lee et al. 7 reported a 28% decline in RDS-specific neonatal mortality rates in the US for the years 1988 through 1991.
The objective of this analysis was to review RDS-specific mortality for the period from 1987 to 1995; to examine changes in the proportion of infant mortality that RDS represented over this time period; to examine changes in birth weight and gestational age specific RDS mortality and to examine changes in race-and sex-specific RDS mortality.
METHODS
Data were obtained from United States Vital Statistics tapes made available from the National Center for Health Statistics. For the years 1987 to 1991 and 1995, linked birth and infant death certificate files were available. No linked files were available for the years 1992 to 1994. We used United States Natality and Mortality file tapes for these 3 years to obtain births and infant specific cause of death information, race and sex information. Because of the lack of linkage to birth certificates for these 3 years, birth weight and gestational agespecific mortality rates cannot be calculated. International Classification for Diseases 9th Revision code 769 as an underlying cause of death was used to indicate a death attributable to RDS; 7704 as an underlying cause of death for
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We performed all analyses using Statistical Analysis Software (SAS), Version 6.12. 8 Statistical tests of changes in rates were accomplished using chi-square tests for trends. Logistic regression was used to estimate average annual changes in mortality rates and to examine interactions between time and race; and time and sex. 9 The formula, (1.00Àodds ratio)Â100, provides an estimate of the average annual decline in rates when the years over which the rate is being examined are included in the logistic regression equation as an ordinal independent variable. Statistical significance was arbitrarily assigned to p values of less than 0.05.
RESULTS
Over the 9-year period there were 21,884 infant deaths attributed to an underlying cause of RDS and 26,308 infant deaths with any mention of RDS as an underlying or secondary cause of death. Over the 9-year period there were 35,989,746 live births available for use in the calculation of mortality rates. There were 23,958,870 live births available from the linked files for the years 1987, 1988, 1989, 1990, 1991 , and 1995 used to calculate birth-weight-and gestational-agespecific RDS mortality rates.
Overall infant mortality decreased 25% over the 9-year period from a rate of 979 deaths/100,000 live births to a rate of 736, whereas mortality attributed to an underlying cause of death of RDS decreased 56% from a rate of 84 to 37 ( Figure 1 ). The decline in RDS mortality accounted for 19% of the decline in the overall infant mortality rate for the 9-year period. Both neonatal and postneonatal mortality attributed to RDS declined during this period. Similarly, the total number of RDS related deaths, including RDS listed as the underlying cause or as a secondary cause declined 51.1% over the 9-year period ( Figure  2 ). RDS listed as a secondary cause of death increased substantially from 17% of the total RDS deaths in 1987 to 31% in 1995.
Mortality from RDS as the underlying cause of death decreased for both white and black races ( Figure 3 ). However, although the RDS rate declined in both races, white infants experienced a 59% decline in rates whereas blacks experienced a 45% decline. This resulted in a significantly increasing relative risk of RDS mortality for blacks compared to whites from 2.02 in 1987 to 2.75 in 1995. This increase in relative risk was significant as measured by the significant interaction term between race and year of birth in a logistic regression model (p<0.001). Over the 9-year period the RDS rate among males declined 58.7% compared to a 51.8% decline in females resulting in slight, but significant decline in the male:female relative risk of RDS mortality from 1.65 (95% confidence interval (CI) =1.53, 1.77) to 1.41 (95% CI=1.57), p value for significant sex and year of birth interaction term=0.02 ( Figure 4 ). The proportion of total infant mortality contributed by RDS decreased over the 9-year period from 8.5% in 1987 to 5.0% in 1995 ( Figure 5 ). Other respiratory related mortality also decreased as a proportion of total infant mortality during this period. This included mortality attributed to an underlying cause of death of respiratory failure, bronchopulmonary dysplasia, and respiratory insufficiency. Of interest was the observation that the proportion of mortality attributed to prematurity increased from a low of 8.7% in 1987 to 13.2% in 1995.
We examined the decline in RDS mortality by birth weight and gestational age categories ( Table 1 ). The lowest average annual decline in RDS as an underlying cause of death was among the smallest infants weighing less than 500 gm (average annual decline=2.7%, 95% CI=0.3, 5.1) and with gestational ages of less than 24 weeks (average annual decline=0.7%, 95% CI= À0.7, 2.1). The largest decline was observed among infants in the 2000-to 2499-gm category (average annual decline=19.6%, 95% CI=15.1, 23.8) and among infants with gestational ages of 33 to 36 weeks (average annual decline=21%, 95% CI=18.0, 23.8).
Using logistic regression we estimated the average annual decline in RDS mortality adjusted for birth weight, race and sex over the 9-year period. The adjusted average annual decline over the 9-year period was 11.8% (95% CI=11.2, 12.4). We also partitioned the 9-year period into a presurfactant era (1987 to 1989) and a postsurfactant era (1990 to 1995). For the presurfactant era there was no significant change in the RDS mortality rate, the point estimate of the average annual rate change actually showed an increase in RDS mortality of 1.8%, but this was not statistically significant (95% CI= À0.8, 4.4). During the postsurfactant era, the adjusted average annual decline in RDS mortality was 11.5% (95% CI=10.5, 12.4).
DISCUSSION
This analysis of US vital statistic mortality data, when examined without regard to birth weight or gestation, documents a marked reduction in RDS related mortality in association with the commercial availability of surfactant in 1990. When examined over a longer period of time, larger reductions in RDS mortality occurred before the immediate pre and post surfactant eras. Malloy et al. 6 reported the reduction in RDS mortality between 1979 and 1983 accounted for 30% of the overall decline in infant mortality compared to the 19% reduction documented in the current analysis. Lee et al. 7 reported that 75% of the decline in infant mortality between 1970 and 1995 occurred between 1970 and 1985. Nevertheless, there can be little doubt that the introduction of surfactant has had a significant impact on RDS-related mortality. Analysis of the 3-year period from 1987 to 1989, before FDA approval of surfactant, shows no significant reduction in RDS related mortality. From 1990 to 1995 the average annual reduction in mortality was 11.5%.
The analysis also demonstrates some realignment in assigning the underlying cause of death with an increase from 8.7% to 13.2% in the proportion of deaths being assigned to an underlying cause of death of prematurity. Related to the increasing number of deaths assigned an underlying cause as prematurity may be the increasing proportion of RDS related deaths assigned as secondary causes of death instead of underlying causes of death. Carver et al. 10 noted in 1993 that rules used by the National Center for Health Statistics to assign the underlying cause of death did not adequately reflect the impact of short gestation. Her study compared the assignment of underlying cause of death assigned by a panel of neonatologists to that of the assignment by a state vital statistics office using NCHS rules. Neonatologists selected short gestation as the underlying cause of death for 82% of very low birth weight records compared to 25% for the office of vital statistics. Our study is consistent with Carver's observation of a probable under estimation of the impact of gestation as an underlying cause of death. However, the increasing proportion of mortality assigned to immaturity observed in our study, may reflect the expectation on the part of physicians that because of the use of surfactant that RDS is less likely to be the underlying cause of death. The misclassification of respiratory related deaths among extremely low birth weight infants seems to be further exaggerated by the failure to identify pneumonia as the underlying cause as demonstrated by Barton et al. 11 Based on autopsy results, Barton reported infection due to pneumonia or chorioamnionitis/funisitis to be the most common primary cause of death in 56 of 111 extremely low birth weight infants weighing 1000 gm or less. RDS was the second most common occurring cause of death among 24 of 111. Thus, correct classification of the underlying cause of *Average annual percent decline in rate determined by logistic regression using the following formula: ( 1.00 À odds ratio ) Â100. Logistic model consisted of RDS deaths / live births = year of birth for each strata of birth weight and gestational age.
death for vital statistic data continues to be a major concern and an element in considering the validity of the changes in rates attributable to any underlying cause of death. However, unless there is a major change in the process of assignment of the underlying cause of death at the national level, following trends in mortality rates for selected underlying causes of death should provide a reasonable estimate of the impact of major therapeutic interventions over time. When birth weight and gestational age are taken into account, several interesting observations are apparent. First, the change in RDS-related mortality varies considerably across birth weight and gestational age categories. As might be expected, there appears to be little or no effect of the introduction of surfactant on RDS related mortality among infants weighing <500 gm and with gestations <24 weeks. There was minimal change in RDS-related mortality among infants weighing 500 to 749 gm until after 1991. The changes in RDS mortality most temporally related to the introduction of surfactant occurred among infants weighing 750 to 1999 gm.
These observations are in line with those of Schoendorf and Kiely 5 who reported lower than expected infant mortality rates for infants weighing 750 to 1750 gm for the year 1990. These authors, however, reported overall mortality and not mortality specific for an underlying cause of RDS or any other respiratory cause. The purpose of their analysis was to test the hypothesis that the introduction of surfactant was responsible for the drop in overall infant mortality for that year. They concluded that the introduction of surfactant during 1990 was only partially responsible for the decline in infant mortality, because the decline in postneonatal mortality among infants weighing 2500 gm or more was responsible for a large portion of the decline in overall infant mortality.
We noted the largest average annual decline in RDS mortality among infants weighing 2000 to 2499 gm and with gestational ages of 33 to 36 weeks. The decline was noted to begin before 1990. Whether overall improvements in neonatal care, the introduction of improved ventilators, or the early trials of surfactant therapy may have preferentially affected decline in mortality in this group of larger infants is uncertain. These more mature preterm infants are, however, less likely to have received antenatal corticosteroids for fetal lung maturation than the preterm infants <32 weeks' gestation. 12 The increasing disparity in RDS mortality rates between blacks and whites described in this analysis is a continuation of a trend reported in a comparison of RDS mortality between blacks and whites for the period 1969 to 1983. 6 In that analysis the relative risk increased from 1.32 in the 1969 to 1973 era to 1.72 for the 1979 to 1983 era. In the current analysis of the period from 1987 to 1995 the relative risk reported increased from 2.02 to 2.75. This increasing black± white disparity in RDS mortality rates, is however, not unique to mortality related to RDS. The black:white ratio for the US has increased for overall infant mortality from 1980 to 1996 from 2.0 to 2.4 and for a specific entity, Sudden infant death syndrome, from 2.01 in 1991 to 2.28 in 1995. 13, 14 Previous reports have suggested that the failure in as great a reduction of RDS mortality among black infants compared to white infants was in part due to more rapid maturation of pulmonary surfactant in black fetuses. 15 ± 19 Many of these previous reports, however, have not corrected for the difference in birth weight distribution between blacks and whites that accounts for the appearance of a lower birth-weight-specific mortality for black very low birth weight infants compared to white very low birth weight infants. 20 Although one report found no difference in the percent of blacks that received surfactant compared to whites, antenatal steroid use was more prevalent among the mothers of the white infants. 5 Thus, it is difficult to attribute the increasing disparity in black:white RDS mortality solely to biologic differences in response to surfactant. Race serves as a proxy for social status in the US. 21 ± 23 and the increasing racial disparity in mortality rates should serve as call to examine more closely the behavioral, cultural, environmental and economic conditions that may be contributing to the disparity.
The decline in the male:female rate ratio over the 9-year period as suggested by the significant interaction reported between sex and year of birth may point to a biologically mediated difference in the impact of surfactant on male infants compared to female infants. This may be further supported by the observation that for all causes of infant mortality the interaction between sex and year of birth did not attain statistical significance (p=0.07). This suggests that the decline in the male:female mortality ratio was more specific for RDS as a cause of death and not seen across all categories of death. The male predominance in infant mortality has been noted in the past. 24 and the greater disparity in mortality between males and females for RDS has been well described. 25 ± 27 In addition, several articles have noted a diminished response in male fetuses to prenatal betamethasone therapy compared to females. 28, 29 The clinical significance of the small decline in the male:female rate ratio from 1.65 in 1987 to 1.41 in 1995 will merit further investigation if the decreasing trend is observed in the coming years.
In summary, we have documented a decline in mortality attributed to an underlying cause of death of RDS over a 9-year period from 1987 to 1995. The decline became most apparent after the introduction of surfactant in 1990. The proportion of mortality attributed to a diagnosis of prematurity has increased suggesting that there may be a shift in the classification of cause of death by practitioners since the introduction of surfactant. Although all birth weight and gestation categories except for the very smallest infants weighing less than 500 gm and less than 24 weeks' gestation appear to have benefited from the introduction of surfactant, the largest declines in RDS mortality have occurred in the larger preterm infants weighing 2000 to 2499 gm and between 33 and 36 weeks' gestation. The decline in RDS mortality among these larger infants began before the introduction of surfactant suggesting other factors affected the decline besides the introduction of surfactant. Finally, the increasing disparity between blacks and whites in RDS mortality should serve as a sentinel event to reenergize efforts to address differences in social, behavioral, cultural, and economic factors that may be contributing to the disparity.
